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NANOPHARMACEUTICALS: INNOVATIVE THERANOSTICS  
FOR THE NEUROLOGICAL DISORDERS
Parichehr Hassanzadeh 
Nanotechnology Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences,  
Tehran, Iran 
Over the past few decades, nanotechnology has emerged as a topic of great interest with a wide range of scientific investigations. 
This highly sophisticated technology covers a vast array of materials and devices including the high-resolution imaging for the 
early diagnosis of diseases and targeted delivery of genes or drugs leading to a more efficient therapeutic outcome. The limited 
efficacy of currently available therapeutic options against the neurological disorders have evoked tremendous efforts towards 
the development of novel treatment strategies. In this respect, multifunctional nanoparticles for targeted delivery of drugs across 
the blood-brain barrier have been designed to improve the bioavailability and reduce the side effects. Nanoengineered materials 
or nanodevices with ability to interact with biological systems including the nervous system have been designed for tracking 
the real-time dynamics of receptors in the central nervous system as well as neuronal recording or stimulation that may result 
in the neuroprotection or neural regeneration. Indeed, application of the cutting-edge nanotechnologies may revolutionize our 
knowledge about the neurophysiology and neurobiology including the cellular or molecular events in neurons leading to the 
more efficient treatments in central nervous system disorders. In the present article, an overview of the theranostic (therapeutic 
and diagnostic) potential of nanopharmaceuticals in the neurological disorders has been provided. Biomed Rev 2014; 25:25-34
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INTRODUCTION
Injuries to the central nervous system (CNS) are clinically 
difficult to manage. For instance, traumatic brain injury (TBI) 
and spinal cord injury (SCI) usually result in the axonal de-
generation and necrosis. In this respect, the victims of SCI 
are left paralyzed and TBI results in the disruption of brain 
parenchyma and permanent neuronal loss (1). The conven-
tional treatment strategies against the neurological disorders 
usually mitigate the degeneration process but do not reverse 
the condition. In the case of neurosurgery, the risk of infections 
and remarkable costs may limit the effectiveness of this thera-
peutic approach. Furthermore, lifelong immunosuppression 
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may be associated with various complications using artificial 
transplants or transplanted organs. In the past few decades, 
nanotechnology has emerged as a rapidly growing interdisci-
plinary field with a vast area for scientific investigations. From 
a historical point of view, nanotechnology was first proposed 
in 1867 by a Scottish physicist, James Clarke Maxwell, who 
developed statistical physics and electromagnetic theory. In 
1959, the Nobel Prize Laureate physicist, Richard Feynman, 
made nanotech-based predictions. His concepts were further 
defined by Professor Norio Taniguchi from Tokyo University 
of Science in 1974, as ‘the separation, consolidation, and 
deformation of materials by one atom or one molecule’. In 
the 1980’s, Dr K. Eric Drexler popularized the previous ideas 
by suggesting the manufacturing of computers or robots even 
smaller than a single cell (2,3). In recent years, application of 
nanotechnology in neuroscience and neurology has provided 
promising research tools and theranostic (therapeutic and 
diagnostic) approaches leading to a better understanding of 
the molecular mechanisms of neurological disorders that may 
revolutionize the ways for therapy strategies and/or diagnostic 
screening (4). Application of the functional scaffold systems 
following the acute or chronic CNS injuries may promote 
the neuronal regeneration. In this respect, three-dimensional 
biodegradable scaffolds have been designed to induce neu-
ronal differentiation (5). Since the blood-brain barrier (BBB) 
prevents the entrance of hydrophilic drugs or large molecules 
into the brain (6), therefore, development of the non-invasive 
techniques based on the modifications of the physicochemical 
properties of the present drug delivery systems or the conjuga-
tion of molecules with antibodies may improve drug delivery 
into the brain. In this respect, various advanced nanomaterials 
have been developed to increase the BBB crossing of drugs 
(7). Therapeutic potential of the highly advanced nanoma-
terials such as gold nanoparticles in brain tumors or myelin 
sheath-coated nanoparticles in multiple sclerosis has been well 
documented (8,9). 
In recent years, development of nanopharmaceuticals with 
improved bioavailability and half-life as well as targeted drug 
delivery systems using dendrimers, lipid- or polymer-based 
nanoparticles has attracted a considerable interest (10-12). In 
regenerative medicine, stem cells with ability to differentiate 
into various cell types including the neurons, have been en-
trapped into the carbon nanofibers or nanotubes for application 
against the neurological disorders (13). Using mesoporous 
nanoparticles, synthetic growth factors may be delivered into 
the motor neurons leading to the long term survival and func-
tional differentiation (14). Moreover, biodegradable polymer 
nanoparticles have been designed as drug delivery nanocarriers 
to encapsulate either hydrophobic or hydrophilic small drug 
molecules and macromolecules such as proteins and nucleic 
acids. Biodegradable polymer systems may provide an opti-
mum range of drug level at a longer period of time leading to 
the enhancement of drug efficacy and patient compliance (15). 
Meanwhile, development of computational models appears 
necessary in order to study the interactions of nanoparticles 
with biological environments leading to the development of 
more sophisticated drug delivery systems (16). 
THERANOSTIC APPLICATION OF NANOTECHNOLOGY  
IN ALZHEIMER’S DISEASE
Alzheimer’s disease is the most common cause of severe 
memory impairment in the elderly and has been considered 
as a major public health problem during the past decades. 
The plaques of amyloid-β (Aβ) and neurofibrillary tangles 
of hyperphosphorylated tau are the pathological hallmarks of 
Alzheimer’s disease which are accompanied by the increased 
levels of metal ions and oxidative stress leading to the death of 
various neuronal subsets including the cholinergic neurons in 
the basal forebrain (17-19). According to the pathophysiologi-
cal features of the disease, the majority of research efforts have 
been focused on in vivo experiments which are associated with 
multiple limitations (20). Based on the remarkable advances 
being made in nanotechnology including the development 
of novel devices and biomaterials for the diagnosis of CNS 
disorders and innovative methods for tissue regeneration, the 
early diagnosis and more effective treatment of Alzheimer’s 
disease has been possible. Using the highly-advanced ap-
proaches including the fluorescence resonance energy transfer 
(FRET) technology and atomic force microscopy (AFM) has 
provided a better understanding of the molecular mechanisms 
of Alzheimer’s disease. AFM scanning probes which are used 
for single-molecule imaging and characterization of biomol-
ecules, provide a real time visualization of the process of Aβ 
fibrilogenesis and in vivo characteristics of amyloid species 
(21). FRET may be used for both in vivo and in vitro systems. 
Using this technology, the molecular mediators implicated in 
the pathogenesis of the disease and subcellular localization of 
Aβ may be identified (22). Bio-barcode assay, a highly sensi-
tive method, is used for the identification of the disease stage 
based on the concentration of biomarkers (23,24). Moreover, 
the localized surface plasmon resonance nanosensors with high 
sensitivity and specificity may be used for patient screening 
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and evaluation of the oligomerization of Aβ (25). Since the 
oxidative damage is an early outcome of the disease pathol-
ogy, development of efficient antioxidants has been the focus 
of intense research. In this respect, derivatives of fullerenes 
have been designed which are potent free-radical scavengers 
and exert neuro protective effects against gluta mate-induced 
excitotoxicity leading to the inhibition of Aβ fibrilogenesis 
(26). Intra ventricular administration of hydrated fullerene into 
the rat prevented Aβ-induced cognitive impairments suggest-
ing the therapeutic significance of fullerenes in Alzheimer’s 
disease (27). Indeed, the inhibition of Aβ plaque formation 
has been one of the most extensively investigated nanotech-
based approaches. In the SHSY-5Y human neuroblastoma 
cell line, nanomicelles composed of phospholipids which 
are stabilized by the addition of polyethylene glycol (PEG) 
has been shown to inhibit the aggregation of Aβ leading to 
the reduced Aβ-induced neuro toxicity (28). Chelating agents 
such as the copper-zinc chelators may also inhibit Aβ plaque 
formation and improve the cognition. Microemulsion nano-
particles conjugated to the copper chelator, D-penicillamine, 
are able to dissolve Aβ aggregates (29-31). In the primary 
cortical neuron cultures, cholesterol-bearing nanogels have 
been shown to reduce the neurotoxicity because of the inhi-
bition of Aβ aggregation (32,33). Regarding the therapeutic 
potential of nano-phytochemicals in Alzheimer’s disease, the 
nanoliposomes of curcumin have been shown to inhibit Aβ ag-
gregation and subsequent cytotoxicity, whereas, administration 
of free curcumin failed to exhibit a significant effect because 
of the low bioavailability (34,35). 
Based on the cholinergic deficit in the disease, current 
treatment options including those based on nanotechnology 
aim to increase the cholinergic neurotransmission. Since 
acetylcholine does not readily cross the BBB and has a short 
half-life, therefore, nanocarriers of acetylcholine such as the 
single-walled carbon nanotubes which are able to cross the 
BBB have been designed. These nanotubes were loaded with 
acetylcholine and restored the cognitive function in kainic 
acid-induced mouse model of Alzheimer’s disease, while, 
acetylcholine showed no effect by itself (36). Moreover, 
poly(n-butylcyanoacrylate) (PBCA) nanoparticles encapsu-
lated with cholinesterase inhibitors may be used for the treat-
ment of demen tia associated to Alzheimer’s disease. These 
nanoparticles adsorb blood apolipoproteins that enable them 
to bind to LDL receptors on BBB endothelial cells leading to 
the facilitation of nanoparticle transcytosis and delivering the 
cholinesterase inhibitors into the brain (37). In order to increase 
BBB penetration, PBCA nanoparticles are usually coated with 
polysorbate-80 leading to the enhanced delivery of drugs into 
the brain (38). These nanoparticles encapsulated with the 
acetylcholinesterase inhibitor, rivastigmine, have significantly 
improved memory and spatial learning (39) indicating their 
therapeutic significance in Alzheimer’s disease.
NANOTECHNOLOGY FOR THE DIAGNOSIS AND TREATMENT  
OF PARKINSON’S DISEASE
Parkinson’s disease, one of the most common neurodegenera-
tive disorders worldwide, is associated with loss of dopaminer-
gic neurons in substan tia nigra pars compacta and accumula-
tion of α-synuclein aggregates  (Lewy bodies) in the brainstem. 
Currently available drugs elevate the levels of dopamine in the 
brain and improve the symptoms, however, they do not alter the 
progression of the disease process (40). The majority of drugs 
are administered orally, therefore, dietary proteins, gastric pH 
or rate of emptying may affect the bioavailability of drugs. 
Other drug delivery systems including the skin patches or 
infusion pumps are also associated with several disadvantages 
(41-44). Moreover, alteration in dopamine receptor sensitivity 
in the basal ganglia may result in the development of adverse 
effects such as levodopa-induced dyskinesia (45,46). In recent 
years, application of nanotechnology either alone or in com-
bination with other therapeutic options including deep brain 
stimulation, tar geted cell transplantation, and gene delivery 
has attracted a considerable interest. Using nanotech-based 
approaches, it would be possible to design devices which 
provide neuroprotection by promoting the regeneration of 
damaged neurons or facilitate the delivery of drugs across 
the BBB (47). Application of the nanosensors results to the 
monitoring of the mechanisms of cell death or detection of the 
neurotransmitter levels within the specific brain regions lead-
ing to the early diagnosis of the disease as well as identification 
of novel drug targets (25). Based on the potential implication 
of oxidative damage in the pathophysiology of Parkinson’s 
disease, the therapeutic potential of fullerenes which exhibit 
antioxidant effects was investigated in the experimental models 
of the disease. Fullerene treatment showed a significant neu-
roprotective effect in 1-methyl-4-phenylpyridinium (MPP+)-
exposed mesencephalic dopaminergic neurons (48,49). In an 
in vivo intranigral iron-infusion model of Parkinson’s disease, 
administration of antioxidant carboxyfullerene prevented the 
degeneration of tyrosine hydroxylase-positive striatal neurons 
(50) indicating the therapeutic significance of fullerenes in 
Parkinson’s disease. 
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Application of the antisense oligonucleotide with func-
tionalized nanogels has provided an efficient transport system 
into the brain that may facilitate the inhibition of activity of 
monoamine oxidase-B (51). This, might enhance dopaminer-
gic neurotransmission which is of therapeutic significance in 
Parkinson’s disease. Moreover, using nanotech-based gene 
delivery approaches may pro mote the survival of nigrostriatal 
dopaminergic neurons or elevate the striatal dopamine content. 
As previously reported, gene delivery vectors promote the 
regenerative capacity within the brain (52). Genes may also be 
delivered via the liposomes. In animal model of Parkinson’s 
disease, the delivery of tyrosine hydroxylase gene through the 
pegylated immunoliposome has restored the enzyme activity 
and motor function (53). Using polycations including the 
polylysine oligomers, DNA may be entrapped into the nano-
particles for delivery into the brain (54). In rat striatum lesioned 
with 6-OHDA, injection of DNA nanoparticles encoding glial 
cell-derived neurotrophic factor (GDNF), a neurotrophic factor 
for midbrain dopaminergic neurons, has been shown to elevate 
the survival of grafted embryonic dopa minergic neurons and 
behav ioral improvement (55). Furthermore, GDNF-loaded 
carbon nanotubes are able to elevate the integration of trans-
planted cells into the striatum (56). Carbon nanotubes loaded 
with nerve growth factor (NGF), the prototypic member of the 
neurotrophin family of proteins, which is critically involved 
in the cell growth, proliferation, and differentiation and me-
diates the therapeutic effects of a wide variety of CNS drugs 
(57-61), are able to promote neurite out growth in dorsal root 
ganglion neurons or PC12 cells (62) indicating their therapeutic 
potential against the neurological disorders. Moreover, elec-
trical stimulation of carbon nanotubes promotes the neuronal 
activity and deep brain stimulation (63) that might be useful 
in Parkinson’s disease. Quantum dots, the biocompatible 
semiconductor nanocrystals, are used for molecular imaging 
and targeted therapy. Since the imbalanced neural activity is 
implicated in the pathogenesis of CNS disorders, therefore, 
quantum dots by generating brain signals and affecting the ion 
channel activity or signalling pathways may restore the normal 
neuronal activity (64) that would be of therapeutic significance 
in various brain disorders including the Parkinson’s disease.
APPLCATION OF NANOTECHNOLOGY IN THE DIAGNOSIS  
AND TREATMENT OF MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is an autoimmune condition in which T 
lymphocytes cross over the broken BBB and attack the myelin 
leading to a gradual demyelination of neurons in the spinal 
cord and brain. Physical disability and neurological symptoms 
associated to MS may be managed by disease-modifying drugs, 
however, the disease process will not stop (65). In recent years, 
advances in nanomedicine have provided greater diagnostic 
and treatment accuracy. Multifunctional nanocarriers with 
targeting agents or magnetic nanoparticles may be used for 
early diagnosis and imaging the lesions (66,67). Superpara-
magnetic particles of iron oxide (SPIO) have been successfully 
applied for tracking the labeled cells within the target tissues 
(68). Moreover, the photoacoustic microscopy provides high-
resolution and noninvasive imaging of the brain (69). 
The reduced perfusion is a typical feature of MS that might 
be involved in the axonal damage and oxidative stress (70). 
Since the efficiency of the conventional treatment strategies 
has remained a challenging issue, therefore, application of the 
targeting strategies such as the site-specific ligand binding may 
increase the drug penetration into the brain. In this context, 
application of the nanomaterials for delivery of CNS-targeted 
neurotherapeutics has been shown to promote the neural elon-
gation and survival (71). Using the purified carbon nanotubes 
as scaffolds induces the formation of nanotube-neuron hybrid 
networks and improve the neuronal performance. Furthermore, 
interaction of carbon nanotubes with stem cell lineage may 
improve the cell behaviour (72). Therefore, carbon nanotubes 
may be successfully applied in nerve tissue engineering that 
might be of therapeutic importance in MS. Fullerenes may 
also be promising therapeutic candidates in MS because of 
their free radical scavenging activity leading to the antioxidant 
and neuroprotective effects. Evidence from the animal models 
of MS indicate that fullerene derivatives by the inhibition of 
glutamate receptors prevent glutamate-induced intracellular 
calcium increase and neuronal excitotoxicity (73,74). Using 
polyamidoamine dendrimers for targeted drug delivery into the 
brain, it has been shown that localization of a drug in activated 
astrocytes and microglia may suppress the neuroinflammation 
in MS affected brain leading to a significant improvement of 
motor function (75). 
Nanotechnology may also be applied in the neurosurgery of 
MS lesions. In this sense, nanosurgery along with the applica-
tion of nanoneuromodulators, nanoscale magnetic materials, 
and nanoimaging may result in the significant neuroprotective 
effects and promote the synaptic connections (76). Neverthe-
less, the early diagnosis of MS appears the best approach for 
the prevention of the irreversible disabilities of the disease. 
This, would be possible using nanoimaging techniques for the 
detection of any defect at cellular or subcellular level.
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APPLICATION OF NANOTECHNOLOGY IN THE SPINAL  
CORD INJURY 
Although the adult spinal cord appears to be capable of axonal 
sprouting and functional reorganization, SCI usually leads to 
the permanent paralysis because of the inability of axons to re-
generate across the lesion. Furthermore, several factors includ-
ing the process of tissue remodelling and migration of reactive 
astrocytes to the lesion site prevent the intrinsic regenerative 
capacity of the spinal cord (77). There are various experimental 
approaches for the regeneration and reconstruction of damaged 
spinal cord including the application of neuroprotective or neu-
rotrophic agents and cell therapy (77a), a promising approach 
for treating a variety of CNS disorders. In SCI, stem cells or 
progenitor cells including the embryonic stem cells (ESCs), 
olfactory ensheathing cells (OECs), Schwann cells, and neural 
progenitor cells may be used for transplantation. Meanwhile, 
the multipotent mesenchymal stem cells (MSCs) appear 
more advantageous for clinical applications as they are easily 
expanded and isolated and exert immunomodulatory effects 
(78,79). Following the intravenous injection or transplanta-
tion into the nervous tissue, MSCs migrate towards the site of 
injury and reduce the lesion volume leading to the functional 
improvement (80). Meanwhile, screening the grafted cells in 
vivo is the essential feature of a successful cell transplantation. 
In this respect, application of SPIO nanoparticles which may be 
visualized by MRI and are easily detected in tissue(s) might be 
so useful. These nanoparticles are consisted of crystalline iron 
oxide core, a polymer shell, and dextran for surface coating 
which prevents particle aggregation (81,82). Dextran-coated 
SPIO nanoparticles have been approved by the US food and 
drug administration (FDA) and are commercially available 
as contrast agents (83). Schwann cells and OECs labelled 
with dextran-coated SPIO have been shown to induce the 
remyelination of axons following the transplantation into the 
demyelinated lesions in rat spinal cord (84,85). Biomaterials 
including the stem cell-seeded hydrogels may be used for 
grafting of the dissociated cells. In recent years, synthetic bio-
degradable porous hydrogels have been developed to increase 
cell growth, differentiation, or adhesion. Hydrogels of poly 
(2-hydroxypropyl)-methacrylamide (PHPMA) implanted into 
the spinal cord lesion provide a scaffold for tissue regeneration 
(86). In the case of large lesions, cell transplantation alone is 
not enough for tissue regeneration and it is essential to bridge 
the lesion site with a permissive environment which fills the 
cavity and enables axonal growth. In this respect, nanofibers 
which may be conjugated to drugs or growth factors are suit-
able candidates for promoting the neural regeneration. Indeed, 
development of nanofiber materials has been an exciting in-
novation in tissue regeneration and drug delivery. The porous 
structure of the nanofibrous network mimics the architecture 
of the extracellular matrix. In addition, the high surface area 
to volume ratio may increase the cell proliferation, differentia-
tion, and adhesion. Using electrospinning technique, various 
electrospun-nanofibers have been developed as the potential 
scaffolds for neural tissue engineering (87,88). Scaffolds based 
on the layers of polymer nanofibers in the case of implantation 
into the hemisected spinal cord leads to the formation of blood 
vessels and neural cell processes (89). Moreover, seeding of 
embryonic spinal cord cells into a nanofiber scaffold promotes 
the regeneration in the transected rat spinal cord (90). 
APPLICATION OF NANOTECHNOLOGY FOR THE MANAGEMENT 
OF AMYOTROPHIC LATERAL SCLEROSIS
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease 
which is caused by the degeneration of lower motor neurons 
in the spinal cord and/or upper motor neurons in the cerebral 
cortex. Diagnosis and treatment of ALS has still remained as a 
major challenge in medicine and symptomatic management is 
the mainstay of treatment in this progressive neurodegenerative 
disorder (91). Following the development of a mouse model 
of the disease, considerable efforts have been made to design 
more efficient therapeutic agents. In this context, cerium oxide 
(CeO2) nanoparticles have been produced which are able to 
reduce free radical-induced damage. CeO2 nanoparticles are 
able to protect the cultured motor neuron-like cells against 
oxidative stress and exhibit neuroprotective effects (92) sug-
gesting the therapeutic significance of these nanoparticles in 
CNS disorders including ALS.
LIPID NANOPARTICLES: STATE-OF-THE-ART CARRIER SYSTEMS 
IN PHARMACEUTICAL NANOTECHNOLOGY
In recent years, considerable research efforts have been 
made to develop the optimized nanocarriers in order to 
overcome the potential problems associated with the previ-
ously developed nanomaterials. In this respect, lipid-based 
colloidal drug delivery systems including the solid lipid na-
noparticles (SLNs) and nanostructured lipid carriers (NLCs) 
have been developed as the alternative carrier systems to the 
polymeric nanoparticles, emulsions, and liposomes. Drugs 
or other active ingredients are protected from the enzymatic 
degradation when loaded within the lipid nanoparticles. 
Furthermore, targeted drug delivery and controlled release 
from the lipid matrix leads to an improved pharmacologic 
profile.  Lipid nanoparticles by increasing the absorption 
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of loaded drug and its residence time in the gastrointestinal 
tract may be administered orally. They may also be used 
as vehicles for topical or parenteral drug delivery (93,94). 
SLNs are the biocompatible colloidal delivery systems with 
several advantages, however, drug expulsion during the 
storage may be occurred due to the lipid polymorphism or 
crystallization of lipid matrix. In addition, SLNs have shown 
limited drug loading capacity (95). Therefore, NLCs which 
are a mixture of solid and liquid lipids with imperfect matrix 
structure were developed to overcome the disadvantages of 
SLNs. NLCs are characterized by good biocompatibility, 
long-term stability, controlled drug release, and high drug 
loading efficiency leading to the reduction of drug dosage 
and adverse effects. NLCs are promising carriers for poorly 
water-soluble drugs that may be due to their potential to 
elevate the solubility of lipophilic drug (96). NLCs have 
been used as a sustained-release drug carrier system for the 
treatment of leukemia (97), antifungal activity (98), psoriasis 
(99) and tumor targeting (100). In human hepatocarcinoma 
cells, entrapment of the inhibitor of epidermal growth factor 
receptor (tyrphostin AG-1478) into the NLCs has resulted 
to a remarkable therapeutic effect (101). NLCs which may 
be produced on large scale, have been loaded with various 
therapeutic agents in our laboratory in order to investigate 
their effects in the ischemic stroke and brain cancer. The 
promising  primary findings represent them as suitable CNS-
targeted drug delivery systems in neurological disorders.
CONCLUSION
The enormous research efforts in the multidisciplinary field 
of nanotechnology have resulted in the amazing growth in the 
production of highly-advanced biomaterials and nanodevices 
including the novel gene or drug delivery systems to over-
come the BBB and provide more efficient treatments. Using 
this cutting-edge technology, a comprehensive knowledge 
about the pathophysiology of neurological diseases has been 
obtained. Application of the sophisticated delivery systems 
of various drugs, growth factors and stem cells have been 
shown to promote the regeneration of damaged tissues that 
might lead to a better prospect for the treatment of neurologi-
cal disorders. In addition, progress being made in the field 
of biomedical nanotechnology has led to the development of 
biomaterials which are able to interact with biological systems 
at sub-cellular levels that may be of both basic and clinical 
significance in the theranostics of various pathological condi-
tions including the neurodegenerative diseases. 
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